| $376M | ||
| $350M | ||
| $215M | ||
| $127M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
Over the last 12 months, insiders at Atossa Therapeutics, Inc. have bought $0 and sold $0 worth of Atossa Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Atossa Therapeutics, Inc. have bought $54,818 and sold $316,167 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 11,239 shares for transaction amount of $9,887 was made by QUAY STEVEN C (President & CEO) on 2025‑05‑21.
| 2025-05-21 | QUAY STEVEN C | President & CEO | 11,239 0.0088% | $0.88 | $9,887 | -12.10% | ||
| 2025-03-26 | Remmel H. Lawrence | director | 10,000 0.008% | $0.70 | $7,000 | +13.12% | ||
| 2024-04-10 | Finn Jonathan | director | 25,000 0.0202% | $1.77 | $44,250 | -26.86% | ||
| 2023-11-15 | Sale | WEAVER GREGORY L | Former EVP, CFO, & Director | 50,000 0.0395% | $0.65 | $32,500 | +103.08% | |
| 2023-06-20 | WEAVER GREGORY L | EVP & CFO | 50,000 0.0401% | $0.97 | $48,500 | -1.18% | ||
| 2021-07-02 | Sale | WEAVER GREGORY L | director | 107,497 0.0883% | $5.58 | $599,833 | -69.09% | |
| 2017-11-15 | Guse Kyle | CFO, Gen Counsel and Secretary | 10,000 0.0857% | $0.34 | $3,369 | -23.53% | ||
| 2017-04-17 | Remmel H. Lawrence | director | 2,500 0.0345% | $0.63 | $1,580 | -24.59% | ||
| 2016-04-01 | Remmel H. Lawrence | director | 1,500 0.0044% | $0.33 | $495 | -57.08% | ||
| 2016-03-09 | QUAY STEVEN C | President & CEO | 15,000 0.0476% | $0.37 | $5,550 | -59.37% | ||
| 2016-03-09 | Chen Shu-Chih | 15,000 0.0476% | $0.37 | $5,550 | -59.37% | |||
| 2016-02-16 | QUAY STEVEN C | President & CEO | 15,000 0.0459% | $0.53 | $7,950 | -54.55% | ||
| 2016-02-16 | Chen Shu-Chih | 15,000 0.0459% | $0.53 | $7,950 | -54.55% | |||
| 2016-01-19 | QUAY STEVEN C | President & CEO | 50,000 0.1586% | $0.20 | $10,000 | +30.00% | ||
| 2016-01-19 | Chen Shu-Chih | 50,000 0.1586% | $0.20 | $10,000 | +30.00% | |||
| 2015-06-12 | Remmel H. Lawrence | director | 5,400 0.02% | $1.30 | $7,020 | -62.99% | ||
| 2013-11-21 | WEAVER GREGORY L | director | 20,000 0.1359% | $2.58 | $51,570 | -30.41% | ||
| 2013-10-01 | Sale | QUAY STEVEN C | CEO | 14,530 0.0922% | $5.66 | $82,211 | -67.88% | |
| 2013-10-01 | Sale | Chen Shu-Chih | Chief Scientific Officer | 14,530 0.0922% | $5.66 | $82,211 | -67.88% | |
| 2013-05-15 | CROSS ALEXANDER D | director | 1,000 0.0068% | $5.49 | $5,490 | -55.87% |
| Chen Shu-Chih | 4348315 50.4947% | $11.24M | 3 | 1 | ||
| CROSS ALEXANDER D | director | 88866 1.032% | $229,718.61 | 1 | 0 | |
| Finn Jonathan | director | 25000 0.2903% | $64,625.00 | 1 | 0 | <0.0001% |
| QUAY STEVEN C | President & CEO | 13898 0.1614% | $35,926.33 | 4 | 1 | |
| Remmel H. Lawrence | director | 10257 0.1191% | $26,514.35 | 5 | 0 | <0.0001% |
| Guse Kyle | CFO, Gen Counsel and Secretary | 10000 0.1161% | $25,850.00 | 1 | 0 | <0.0001% |
| WEAVER GREGORY L | Former EVP, CFO, & Director | 55 0.0006% | $142.18 | 2 | 2 | <0.0001% |
$18,815,063 | 62 | -6.39% | $20.23M | |
$6,204,522 | 45 | 1.91% | $24.48M | |
$94,610,184 | 33 | -23.48% | $17.96M | |
$95,303,339 | 30 | -13.78% | $32.31M | |
$241,165 | 22 | -16.72% | $32.63M | |
$114,619,342 | 20 | -7.41% | $14.79M | |
$351,813 | 19 | 21.51% | $32.18M | |
$91,696,644 | 18 | -4.72% | $19.16M | |
$1,246,170 | 12 | 65.67% | $15.37M | |
$13,595,542 | 9 | -16.74% | $17.97M | |
$189,648 | 9 | -52.20% | $32.31M | |
$654,995 | 7 | -60.00% | $26.37M | |
$8,470,804 | 6 | -13.28% | $17.48M | |
Atossa Therapeutics, Inc. (ATOS) | $104,699 | 5 | -12.61% | $22.26M |
$18,186,879 | 4 | 49.41% | $18.78M | |
$16,526,031 | 2 | -0.85% | $28.1M | |
$100,266 | 2 | 3.17% | $24.86M | |
$500,000 | 1 | -22.94% | $19.33M | |
$30,190 | 1 | -42.39% | $31.69M |
| Increased Positions | 34 | +48.57% | 293,926 | +22.66% |
| Decreased Positions | 23 | -32.86% | 95,316 | -7.35% |
| New Positions | 13 | New | 86,749 | New |
| Sold Out Positions | 12 | Sold Out | 48,578 | Sold Out |
| Total Postitions | 81 | +15.71% | 1M | +15.31% |
| Vanguard Group Inc | $3,836.00 | 4.71% | 6.08M | +245,717 | +4.21% | 2025-09-30 |
| Ameriprise Financial Inc | $1,862.00 | 2.29% | 2.95M | -21,700 | -0.73% | 2025-09-30 |
| Blackrock, Inc. | $1,261.00 | 1.55% | 2M | -150,383 | -7% | 2025-09-30 |
| Millennium Management Llc | $1,053.00 | 1.29% | 1.67M | -378,887 | -18.5% | 2025-09-30 |
| Renaissance Technologies Llc | $977.00 | 1.2% | 1.55M | -263,588 | -14.54% | 2025-09-30 |
| Geode Capital Management, Llc | $860.00 | 1.06% | 1.36M | +61,903 | +4.76% | 2025-09-30 |
| State Street Corp | $287.00 | 0.35% | 454,495 | -62,076 | -12.02% | 2025-09-30 |
| Gsa Capital Partners Llp | $196.00 | 0.24% | 310,754 | +259,725 | +508.98% | 2025-09-30 |
| Northern Trust Corp | $166.00 | 0.2% | 263,377 | 0 | 0% | 2025-09-30 |
| Citadel Advisors Llc | $166.00 | 0.2% | 263,369 | +176,451 | +203.01% | 2025-09-30 |